Business Novartis’ new heart failure medicine LCZ696, approved by FDA to reduce risk of cardiovascular death and heart failure hospitalization by Michele Hobeika July 14, 2015 by Michele Hobeika July 14, 2015 Beirut, Lebanon, July 13, 2015– Novartis announced that the US Food and Drug Administration… 0 FacebookTwitterPinterestEmail